Betalutin: Ph I LYMRIT 37-05 started

Nordic Nanovector began the open-label, dose-escalation, international Phase I LYMRIT 37-05 trial to evaluate injections of Betalutin in up to 24 patients who are ineligible for an autologous stem cel...